Written by: Aaron Katsman | June 9, 2008
Aaron Katsman
IsraelNewsletter.com
What could a horse with a 38-1 shot of winning, and a small country with only 7 million people surrounded by enemies, have in common? The answer: They are both longshots and underdogs that have prevailed and flourished despite predictions to the contrary. For those not familiar, the horse Da’ Tara, won Saturday’s running of the Belmont Stakes, spoiling Big Brown’s attempt at winning horse racings triple crown. Big Brown was considered a lock to be the first horse to capture the elusive triple crown in 30 years. Instead, he was upstaged by a horse that no one had paid any attention to.
Likewise, the tiny country of Israel, has flourished despite predictions of destruction. In a great article in The New York Times, Thomas Friedman asks the following question: “Question: What do America’s premier investor, Warren Buffett, and Iran’s toxic president, Mahmoud Ahmadinejad, have in common? Answer: They’ve both made a bet about Israel’s future.” (Continue »)
Comments (1)
Category:
Uncategorized
Tags:
Belmont Stakes,
Big Brown,
Da'Tara,
horse racings triple crown,
international investment,
iran,
iscar,
israel opportunity investor,
israeli horses,
Mahmoud Ahmadinejad,
new york times,
Thomas Friedman,
Triple Crown,
underdogs,
Warren Buffett
Written by: Aaron Katsman | March 31, 2008
Aaron Katsman
www.IsraelNewsletter.com
Today’s news that Gilat Satellite Networks (GILT) is going to be acquired for $11.40 a share, should come as no surprise to IOI readers. We hate to brag, but we called this one a while back. This continues the IOI trend of predicting M&A, as we called the ECI Telecom deal as well. Maybe it’s time that you subscribe to our premium product( Subtle huh).
The price is about a 10% premium to Friday’s closing price.
The investor group includes Mivtach Shamir, The Gores Group LLC, DGB Investments Inc. and companies affiliated with Roy Ben-Yami, Ami Lustig and Eytan Stibbe.
While I thought that the company should remain independent and continue to grow, for the company and large investors, the deal was too good to pass up.
For merger arbitrage investors, keep your eye on how Gilat trades over the next few months. With the deal set to be completed in September, any weakness in the stock could make for an interesting play. After all a potential 6-10% return in 5 months, is nothing to sneeze at, especially in markets that can’t seem to go up.
Disclosure: Author’s fund holds a position in GILT. He holds no position in any other stock mentioned as of 3/31/08.
Please see our Disclaimer HERE.
NEW! Introducing Israel Opportunity Investor, our monthly subscription-only newsletter. Stay ahead of the game and make smart decisions in Israel stocks. Go here to learn more.
Aaron Katsman is Managing Editor of the Israel Opportunity Investor newsletter. He is lead portfolio manager for the Israel Growth Portfolio and Managing Director of America Israel Investment Associates, LLC. For more information, go to www.israelnewsletter.com or call 1-888-327-6179, or email aaron@profile-financial.com.
Written by: Zack Miller | February 10, 2008
Not wanting to be remiss in giving an update on Israel Opportunity Investor portfolio member, Alvarion (Nasdaq: ALVR), we want to chime in with our two cents. We’ve been positive on the stock and have seen our thesis — that of further global uptake of fixed mobile services — came to fruition and even surpass what we were expecting. This is a critical lesson for investors: while stocks may perform financially as planned, how they trade is another matter.
We’ve seen the stock essentially pulverized by fear of weak global markets. Telecom spending typically gets pushed out during turbulent times.
That said, Alvarion’s not seeing that yet. In fact, while we continue to think the stock has a lot going for it, we are sensing a rising sense of negativity on the stock, driving it down off of what was ultimately a good reporting season and not too bad guidance in the headwinds of a weak dollar.
An article ran in SmallCapInvestor last week after Alvarion announced earnings and looked at how analysts were sizing up ALVR’s results. The way I read the results and how Susquehanna addressed them?
- Alvarion had a Q4 ahead of estimates and saw WiMAX revenues up over 50% from 2006.
- Higher operating expenses are certainly a negative for the company but the company attributed this to a weak US dollar.
What many investors and even analysts don’t appreciate is that the dollar has fallen like a rock versus the Israeli shekel. Israeli firms like Alvarion that trade in the US and are priced in dollars but conduct R&D/production in Israel are all feeling a squeeze. We’ve heard this from numerous Israeli CEOs. When the time comes that the dollar ultimately strengthens against the shekel, we’ll see a natural reversal in these numbers. My point here is that when numbers like this are clearly attributed to fluctuations in the dollar, earnings gains/misses are not organic changes in the business model.
This same analyst report that SmallCapInvestor disparaged actually comes out pretty positive on Alvarion. Susquehanna likes the Q4 surprise, likes the WiMAX opportunity, and Alvarion’s stable of international customers. Long term investors in Israeli stocks trading in the US will find it somewhat funny to think that a particularly strong shekel is weighing on earnings.
Disclosure: Author’s fund holds a position in ALVR and is long the stock as of 2/8/08.
Please see our Disclaimer HERE.
NEW! Introducing Israel Opportunity Investor, our monthly subscription-only newsletter. Stay ahead of the game and make smart decisions in Israel stocks. Go here to learn more.
Comments (1)
Category:
alvarion,
alvr,
portfolio,
shekel,
telecom,
wimax
Tags:
alvarion,
alvr,
israel newsletter,
israel opportunity investor,
israel stocks in the US,
newsletter,
technology,
telecom,
wimax
Written by: Zack Miller | February 7, 2008
Someone called us recently to ask about a newish ETF called the SPDR Emerging Middle East & Africa (Amex: GAF). The ETF
is heavily weighted around three countries — South Africa (65%), Israel (17%) and Egypt (6%).
There are other ETFs that include exposure to Israel but as far as we know, this ETF currently has the largest exposure.
Israel as a destination
We like Israel (but hey, we’re biased). While Israel is not putting up double-digit GDP growth like China, we are seeing close to 4-5%.
Not too shabby.
Foreign capital is flowing
We’re continuing to see money coming into Israel looking for a home. Canaan Partners just announced another fund that will be targeting opportunities in Israel.
Can Israel do better?
And if you ask Netanyahu [subscription required], we could see close to 8%, if certain pro-market policies are put into place. Even Netanyahu’s detractors credit his cuts in welfare benefits, the removal of remaining currency and capital controls, and liberalization of the banking sector as cutting the way for an amazing economic recovery.
Check out Eze Vidra’s post, “Israel 2008: What the Bulls and the Bears are saying“, for some good forecasts of what various analysts are looking for from the Israeli economy in 2008.
What does the ETF hold?
Check out the GAF’s holdings. What you’ll see is that Israel’s 11% weighting is driven by the fact that Teva Pharmaceuticals (Nasdaq: TEVA) is the ETF’s largest holding at over a whopping 9%. We then see Israel Chemical (2%), Bank Leumi (1.43%) and Bank Hapoalim (1.41%). Elbit Systems (Nasdaq: ESLT) is also in there (1.06%). The rest of the Israel holdings each account for less than 1% of the SPDR Emerging Middle East & Africa Fund.
Investors in Israel from abroad may like the fact that this fund holds locally traded companies that aren’t dually listed or carry a corresponding ADR in the US.
So, what’s an investor interested in Israel to do?
That said, 17% of a fund that has exposure to really different economies may not be enough for foreign investors looking to trade locally-traded Israeli shares. Also, TEVA’s weighting at 9% of the overall fund means that Teva alone accounts for over 50% of the total Israeli exposure.
Teva may be a great company but it’s not indicative of the Israeli market as a whole. I’d like to see more exposure to Israel Chemicals, the Israeli banks, Bezeq, 012.Smile (Nasdaq: SMLC), the Mobile phone carries including Partner (Nasdaq: PTNR) and Cellcom (NYSE: CEL), let alone all the newer, smaller, tech firms listed locally.
What about mobile fixed telecom players like Alvarion (Nasdaq: ALVR) and Ceragon (Nasdaq: CRNT)? Both have taken a worse beating than Britney has received from the paparazzi.
I’d like to see a country ETF also include local retailers like Blue Square-Israel (NYSE: BSI)
Israel investors may be better off weighting for new offerings in the works as we hear that Barclays and another firm has an Israel ETF in registration.
Please see our Disclaimer HERE.
NEW! Introducing Israel Opportunity Investor, our monthly subscription-only newsletter. Stay ahead of the game and make smart decisions in Israel stocks. Go here to learn more.
Comments (6)
Category:
Bank of Israel,
IPO,
VC,
economy,
in the news,
investing,
israel
Tags:
alvarion,
alvr,
Bank of Israel,
CEL;partner; cellphone; Israel,
ceragon,
israel ingenuity,
israel newsletter,
israel opportunity investor,
israel stocks,
israel stocks in the US,
israeli economy,
israeli stocks; Ehud Olmert,
Teva,
VC